Tesamorelin for Women: What the Evidence and FDA Label Actually Say

Women searching for tesamorelin often encounter claims that it can reduce abdominal fat, improve body composition or function as a general weight-loss peptide. The evidence is considerably more specific.

Women can be prescribed tesamorelin when a licensed clinician determines that it is medically appropriate. However, the FDA-approved tesamorelin product, EGRIFTA WR, is approved for one purpose: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved as a general weight-loss medication, menopause treatment or cosmetic fat-loss injection.

Understanding that distinction is essential before considering treatment.

Written by the NovaGenix Editorial Team · Medically reviewed by Timothy W. Mackey, D.O., Medical Director
Florida License OS9185 · Last medically reviewed: September 17, 2026

What is tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, commonly abbreviated GHRH. It signals the pituitary gland to release more of the body's own growth hormone, which subsequently increases insulin-like growth factor 1, or IGF-1.

Tesamorelin is therefore different from human growth hormone. It stimulates the body's growth-hormone pathway rather than supplying recombinant growth hormone directly.

For a detailed comparison, read Tesamorelin vs. HGH: Differences, Uses and Safety.

Can women take tesamorelin?

Yes, women were eligible for the randomized clinical trials used to establish tesamorelin's effectiveness. The FDA label included separate waist and waist-to-hip-ratio eligibility criteria for women.

Women represented a minority of participants, however. Approximately 14% of participants in one pivotal study and 16% in the other were women. The overall trial results therefore apply to study populations that included women, but the evidence base contains substantially more male participants.

The FDA-approved indication does not exclude women, and the label does not provide a different dose based on sex. That does not mean tesamorelin is appropriate for every woman seeking help with abdominal fat.

What is tesamorelin approved to treat?

EGRIFTA WR is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

Lipodystrophy involves abnormal changes in fat distribution. In some people living with HIV, excess visceral fat can accumulate deep within the abdomen. This is different from ordinary weight gain and from the subcutaneous fat that can be pinched beneath the skin.

Tesamorelin is not FDA-approved for:

• General weight loss
• Menopause-related weight gain
• Cosmetic spot reduction
• Obesity treatment
• Routine anti-aging therapy
• Improving athletic performance

Any use outside the approved indication is off-label and requires an individualized medical evaluation.

Does tesamorelin cause weight loss in women?

Tesamorelin should not be described as a conventional weight-loss medication. The FDA labeling specifically states that it is not indicated for weight-loss management and that it has a weight-neutral effect.

In the pivotal trials, tesamorelin reduced visceral adipose tissue while producing little overall change in body weight. That means a patient could experience a change in a specific abdominal-fat compartment without seeing a major change on the scale.

Women whose primary goal is overall weight reduction may need an entirely different evaluation and treatment strategy. Medications such as semaglutide and tirzepatide work through different biological pathways and have different approved uses, benefits and risks.

Learn more about medically supervised weight-loss programs.

What did the clinical trials show?

Two randomized, double-blind, placebo-controlled studies evaluated tesamorelin in adults with HIV-associated lipodystrophy and excess abdominal fat.

After 26 weeks, tesamorelin reduced visceral adipose tissue compared with placebo. The studies also reported modest reductions in waist circumference and trunk fat, along with increases in lean body mass. Overall body weight changed very little.

These findings should not be generalized to every woman with abdominal weight gain. The participants had a specific medical condition, most were men, and the studies were not designed to establish tesamorelin as a treatment for routine obesity or menopausal body-composition changes.

The studies also showed that visceral fat tended to return after treatment was discontinued. Tesamorelin should therefore not be presented as a permanent fat-removal procedure.

Is tesamorelin used for menopause-related abdominal fat?

Tesamorelin is not FDA-approved to treat menopause, perimenopause or menopause-associated weight gain.

Changes in estrogen, sleep, insulin sensitivity, muscle mass and activity can all influence body composition during menopause. These concerns deserve a broader evaluation rather than the assumption that one peptide is the answer.

A clinician may need to review:

• Menopause symptoms and menstrual history
• Estradiol, progesterone and testosterone when clinically indicated
• Thyroid function
• Glucose and HbA1c
• Medications
• Sleep quality
• Nutrition and activity
• Existing cardiovascular or metabolic risk factors

Tesamorelin should not be substituted for a proper menopause or metabolic evaluation.

Can tesamorelin be used during pregnancy?

No. EGRIFTA WR is contraindicated during pregnancy.

The FDA labeling states that modifying visceral fat during pregnancy provides no known benefit and could result in fetal harm. A woman who becomes pregnant while using the medication should discontinue it and contact her healthcare provider.

Women who are pregnant, planning pregnancy or could become pregnant should discuss this with their clinician before treatment is considered.

What side effects should women know about?

Tesamorelin raises growth hormone and IGF-1. Its potential effects extend beyond abdominal fat.

Important risks and adverse effects include:

• Elevated IGF-1
• Increased blood glucose or development of diabetes
• Fluid retention
• Joint discomfort
• Muscle pain
• Carpal tunnel symptoms
• Injection-site redness, itching, pain or bruising
• Hypersensitivity reactions

Tesamorelin is contraindicated in patients with active malignancy, certain disruptions of the hypothalamic-pituitary axis, known hypersensitivity to the medication and pregnancy.

A history of cancer, diabetes, prediabetes, pituitary disease, head trauma or head radiation requires particular attention during the medical evaluation.

What monitoring may be required?

Appropriate monitoring depends on the patient's medical history and the reason treatment is being considered. Evaluation may include:

• IGF-1
• Fasting glucose
• HbA1c
• Medical and cancer history
• Medication review
• Body-composition assessment
• Follow-up for swelling, joint symptoms and injection reactions

Women with diabetes may also require monitoring for diabetic retinopathy. Laboratory testing should be interpreted by the prescribing clinician rather than used to create a self-directed peptide protocol.

How is FDA-approved tesamorelin administered?

The current FDA-approved formulation, EGRIFTA WR, is administered by subcutaneous injection once daily. The labeled dose is 1.28 mg, or 0.16 mL of the properly reconstituted solution.

The label directs patients to inject into the abdomen, rotate injection sites and avoid the navel, scar tissue and bruised areas.

EGRIFTA WR and earlier EGRIFTA formulations have different strengths, doses and preparation instructions. They are not interchangeable.

Because tesamorelin is a 44-amino-acid peptide, it exceeds the 40-amino-acid threshold that separates drugs from biologics and is regulated as a biological product. Biologics are not eligible for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. A compounded "tesamorelin" preparation is therefore not a lawful alternative to the FDA-approved product, and NovaGenix does not treat it as one.

Patients should follow the instructions supplied with the exact medication dispensed to them.

See the complete NovaGenix guide to tesamorelin dosage, injection sites and FDA status.

Is tesamorelin appropriate for women without HIV-associated lipodystrophy?

That cannot be determined from a website or from abdominal appearance alone.

For women who do not have the approved condition, treatment would be off-label. A physician would need to determine whether there is a medically defensible reason to consider it, whether the potential benefits justify the risks and whether another treatment better matches the patient's goals.

A consultation should not be treated as a guarantee that tesamorelin will be prescribed.

Frequently asked questions

Do women use a different tesamorelin dose than men?

The FDA label does not provide a sex-specific dose. EGRIFTA WR has a labeled dose of 1.28 mg subcutaneously once daily for adults with the approved indication. Individual patients should follow the instructions from their prescriber and pharmacy.

Does tesamorelin reduce the fat women can pinch?

Tesamorelin's approved role concerns visceral fat located deep within the abdomen. It should not be assumed to eliminate superficial subcutaneous fat on the abdomen, hips or thighs.

Can tesamorelin treat menopause weight gain?

Tesamorelin is not FDA-approved for menopause or menopause-related weight gain. Women with these concerns should receive a broader hormonal and metabolic evaluation.

Can tesamorelin be taken with hormone replacement therapy?

There is no universal answer. The clinician must review the patient's medications, medical history, laboratory results and treatment goals. Patients should not combine therapies without guidance from the prescribing professionals.

Is tesamorelin the same as a GLP-1 medication?

No. Tesamorelin stimulates growth-hormone release. GLP-1 medications work through incretin pathways that influence appetite, glucose regulation and gastric emptying. They have different approved indications and safety considerations.

Can women get compounded tesamorelin?

Tesamorelin is regulated as a biological product because its chain exceeds 40 amino acids, and biologics cannot be compounded under section 503A. Products marketed online as compounded or research-grade tesamorelin are not FDA-approved and are not dispensed through NovaGenix.

Physician-led tesamorelin evaluation in Florida

NovaGenix provides physician-led hormone, peptide and metabolic evaluations from its Jupiter, Florida clinic. Dr. Timothy Mackey, D.O. reviews medical history, laboratory findings, contraindications and treatment goals before determining whether a medication is appropriate.

Eligible Florida patients may be evaluated through telemedicine when clinically appropriate. Treatment is never guaranteed solely because a consultation is requested.

Call 561-277-8260 or request a consultation.

NovaGenix Health & Wellness | 609 N. Hepburn Ave., Suite 106, Jupiter, FL 33458 | Call or text 561-277-8260

Medical references

FDA-approved EGRIFTA WR prescribing information

FDA: Bulk Drug Substances Used in Compounding Under Section 503A

NovaGenix tesamorelin treatment guide

Tesamorelin vs. HGH

Medical disclaimer: This article is for general educational purposes and does not provide medical advice, diagnosis or an individualized treatment recommendation. Treatment decisions require evaluation by a qualified healthcare professional.